ICCC
Immucell Corp.

647
Mkt Cap
$55.29M
Volume
8,680.00
52W High
$7.60
52W Low
$4.28
PE Ratio
23.45
ICCC Fundamentals
Price
$6.22
Prev Close
$6.07
Open
$5.95
50D MA
$5.83
Beta
0.33
Avg. Volume
18,765.21
EPS (Annual)
-$0.2641
P/B
1.84
Rev/Employee
$353,242.25
Loading...
Loading...
News
all
press releases
ImmuCell's Two-Product Edge in Cattle Health Fuels Growth
ICCC's innovative, antibiotic-free cattle health products drive margin recovery, real-world adoption and stock gains.
Zacks·8d ago
News Placeholder
More News
News Placeholder
ICCC Stock Down Despite Y/Y Q3 Earnings Improvement & Margin Strength
ImmuCell tumbles despite stronger margins and a rebound in EPS, as backlog dynamics pressure quarterly sales while management highlights improving operations.
Zacks·22d ago
News Placeholder
ImmuCell (NASDAQ:ICCC) Announces Quarterly Earnings Results
ImmuCell (NASDAQ:ICCC - Get Free Report) released its quarterly earnings results on Thursday. The biotechnology company reported ($0.02) EPS for the quarter. ImmuCell had a return on equity of 6.25...
MarketBeat·27d ago
News Placeholder
ImmuCell (NASDAQ:ICCC) Stock Crosses Above 200 Day Moving Average - Time to Sell?
ImmuCell (NASDAQ:ICCC) Stock Price Crosses Above 200-Day Moving Average - Here's Why...
MarketBeat·29d ago
News Placeholder
ImmuCell (NASDAQ:ICCC) Shares Pass Above Two Hundred Day Moving Average - Time to Sell?
ImmuCell (NASDAQ:ICCC) Stock Passes Above Two Hundred Day Moving Average - What's Next...
MarketBeat·29d ago
News Placeholder
The Zacks Analyst Blog Highlights SAP, Novartis, Philip Morris International, ImmuCell and ClearOne
SAP's cloud and AI push, Novartis' strong drug lineup, and Philip Morris' smoke-free growth headline Zacks' latest analyst picks.
Zacks·2mo ago
News Placeholder
Top Stock Reports for SAP, Novartis & Philip Morris
SAP, Novartis and Philip Morris headline today's top Zacks reports, each showing strong momentum and strategic growth drivers despite industry headwinds.
Zacks·2mo ago
News Placeholder
FONAR's Stock Advances 5% in Three Months: Key Trends Ahead
FONR leverages hybrid MRI tech and a strong balance sheet to navigate industry headwinds, though rising costs and regulatory risks tied to claim collections remain key challenges.
Zacks·3mo ago
News Placeholder
ImmuCell Swings to Q2 Profit on Strong Sales, Shares Still Slide
ICCC posts Q2 profit on higher sales and margins, but shares fall as investors weigh one-time boosts and Re-Tain's delayed commercialization.
Zacks·4mo ago
News Placeholder
ImmuCell Upgraded to Outperform on Sales Surge & FDA Upside
ICCC earns "Outperform" rating with record Q1 sales, margin gains and growth potential tied to Re-Tain's FDA progress and new product formats.
Zacks·5mo ago

Latest ICCC News

View

Advertisement|Remove ads.

Advertisement|Remove ads.